IBio And Caliber Biotherapeutics Establish License And Collaboration Relationship

NEWARK, Del. and BRYAN, Texas, Feb. 19, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO), and Caliber Biotherapeutics LLC (Caliber) today announced execution of a License and Collaboration Agreement for development and production of recombinant plant-based biopharmaceuticals using iBio's proprietary iBioLaunch™ technology and Caliber's unique and proprietary plant-based manufacturing capabilities.

(Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO) (Logo:  http://photos.prnewswire.com/prnh/20130219/NY61582LOGO)

The new relationship establishes a turn-key plant-based biopharmaceutical development capability, from the earliest stage of product selection and optimization through large-scale production.  iBio and Caliber will use their combined capabilities for their own product portfolios, starting with an undisclosed monoclonal antibody for oncology indications, where Caliber and its affiliates have demonstrated expertise.  The Companies also will make their combined capabilities available to third parties through licensing and partnering arrangements for other recombinant plant-based biotherapeutics and vaccines.

iBio's patented iBioLaunch™ technology, developed over nine years at a cost of more than US$100 million, causes common green plants to produce commercial quantities of targeted human proteins in proper form for use as the active pharmaceutical ingredients for the development and production of biopharmaceuticals.  Caliber owns and operates the world's largest-capacity cGMP commercial manufacturing facility for plant-made biopharmaceutical products.

iBio's technology platform is broadly applicable to recombinant vaccines and biotherapeutic products, including:  monoclonal antibodies; proteins otherwise derived from blood plasma; and replacement enzymes used to treat a variety of orphan diseases.  The technology has demonstrated capabilities to express proteins that were not commercially feasible to produce using other systems, and unlike technologies dependent on transgenic cells and organisms, utilizes advanced informatics and new synthetic biology techniques for superior clinical product design and delivery.  Human clinical trials of product candidates produced with iBio's technology have been funded by the U.S. Department of Defense and the Bill & Melinda Gates Foundation.

1 2 3 Next › Last »